AMARILLO, Texas — Maxor National Pharmacy Services LLC has completed its acquisition of Pharmaceutical Specialties Inc. (PSI).

Financial terms of the deal, announced in September, weren’t disclosed. Bogart, Ga.-based PSI specializes in pulmonary medicine (including cystic fibrosis and bronchiectasis), endocrine medicine (including growth hormone) and gastrointestinal medicine (including hepatitis C and Crohn’s disease).

Maxor said that, together, its Maxor Specialty and IV Solutions businesses and PSI make the company an industry-leading specialty pharmacy, offering extensive clinical expertise and high-touch service models to patients, physicians, drug manufacturers and payers.

“Maxor and PSI have both offered innovative, clinically focused specialty pharmacy services for more than 20 years,” Maxor chief executive officer Mike Ellis commented when the PSI acquisition was announced. “Combining these two companies brings national scale, clinical excellence and operational capabilities while maintaining individual patient focus, enabling us to further lead and serve our specialty pharmacy customers.”

Amarillo, Texas-based Maxor’s three primary businesses are Maxor Specialty and IV Solutions, which provides specialty pharmacy, respiratory and home infusion services; MaxorPlus, providing client and patient-focused pharmacy benefit management services; and Maxor Pharmacy Management and Consulting Services, which provides on-site outpatient pharmacy management, 340B audits, and consulting services to hospitals, health systems, federally qualified health plans, DSH hospitals and self-funded employer groups.

Maxor has 17 pharmacy locations, including IV Solutions sites, in California, Colorado, New York, Tennessee, Texas and Washington.